Literature DB >> 7671018

Components of the renin-angiotensin system in adipose tissue: changes with maturation and adipose mass enlargement.

J B Harp1, M DiGirolamo.   

Abstract

White adipose tissue is a rich source of angiotensinogen protein and mRNA. Studies in clonal cells suggest that angiotensinogen, and its cleavage product, angiotensin II, are involved in preadipocyte differentiation into mature fat cells. No studies have determined whether angiotensinogen is also involved in adipose tissue development in vivo. In this report, we studied male Wistar rats at two stages of development to determine if angiotensinogen protein and mRNA are increased in retroperitoneal fat depots of rapidly growing young, lean, 8-week-old rats compared to 26-week-old rats that are fatter, but are undergoing less rapid adipose tissue growth. We also assessed renin mRNA and angiotensin I-generating activity, since it is less clear whether renin is locally produced in adipose tissue. We found that angiotensin I-generating activity was measurable in adipose tissue and adipocytes, but renin mRNA was undetectable by northern blot analysis. Angiotensinogen mRNA was abundant in adipocytes, but was absent in stromal-vascular cells of adipose tissue. Angiotensinogen content per 10 million fat cells was approximately threefold higher in 8-week-old rats compared to 26-week-old rats (p < .0002). Angiotensinogen mRNA was approximately twofold higher in adipocytes of 8-week-old rats compared to 26-week-old rats. The age-related decline in angiotensinogen protein and mRNA indicates that the local renin-angiotensin system may play an important role in adipose tissue growth, and possibly contribute to the changes in adipose mass and cellularity seen in old senescent rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671018     DOI: 10.1093/gerona/50a.5.b270

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  8 in total

Review 1.  Obesity and hypertension.

Authors:  E Faloia; G Giacchetti; F Mantero
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

2.  Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice.

Authors:  Frederique Yiannikouris; Michael Karounos; Richard Charnigo; Victoria L English; Debra L Rateri; Alan Daugherty; Lisa A Cassis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-09       Impact factor: 3.619

Review 3.  Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target.

Authors:  Reza Aghamohammadzadeh; Sarah Withers; Fiona Lynch; Adam Greenstein; R Malik; Anthony Heagerty
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells.

Authors:  J Aubert; C Darimont; I Safonova; G Ailhaud; R Negrel
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

5.  Regulation by fatty acids of angiotensinogen gene expression in preadipose cells.

Authors:  I Safonova; J Aubert; R Negrel; G Ailhaud
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

6.  Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values.

Authors:  Aldo S Villecco; Cinzia Cocci; Maurizio Di Emidio
Journal:  Curr Ther Res Clin Exp       Date:  2004-03

7.  Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity.

Authors:  Paula Stucchi; Victoria Cano; Mariano Ruiz-Gayo; María S Fernández-Alfonso
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

8.  Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects.

Authors:  E Faloia; C Gatti; M A Camilloni; B Mariniello; C Sardu; G G M Garrapa; F Mantero; G Giacchetti
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.